Sandbox:Preeti: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism
! colspan="12" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations
! colspan="11" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations
! colspan="10" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings
! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|-
! colspan="9" align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab findings
! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab findings
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Imaging
|-
|-
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |LFT
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
Line 38: Line 36:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Arthritis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
Line 44: Line 41:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
|-
|-
! colspan="30" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL
! colspan="27" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |
! align="center" style="background:#4479BA; color: #FFFFFF;" + |
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 76: Line 70:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="30" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
! colspan="27" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
Line 82: Line 76:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Precursor B-cell Lymphoma
* Precursor B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 117: Line 108:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Second most common subtype of NHL
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 131: Line 123:
* Central and peripheral lymphadenopathy
* Central and peripheral lymphadenopathy
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Seizures]]
* [[Seizures]]
Line 148: Line 139:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Most common clinically indolent NHL
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!
Line 173: Line 163:
| align="center" style="background:#F5F5F5;" + |Generalized lymphadenopathy
| align="center" style="background:#F5F5F5;" + |Generalized lymphadenopathy
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Extranodal involvement of GI tract, lungs, and CNS
* Extranodal involvement of GI tract, lungs, and CNS
Line 182: Line 171:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 193: Line 181:
* Nodular appearance
* Nodular appearance
| align="center" style="background:#F5F5F5;" + |Elevated LDH
| align="center" style="background:#F5F5F5;" + |Elevated LDH
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 220: Line 207:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Painless rapidly enlarging [[lymph nodes]]
* Painless rapidly enlarging [[lymph nodes]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 228: Line 214:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
*
*
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 242: Line 227:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Hypergammaglobulinemia
* Hypergammaglobulinemia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 261: Line 245:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Arthritis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC
Line 267: Line 250:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LFT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other lab findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other lab findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Imaging
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
Line 301: Line 282:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Swollen lymph nodes]] in the neck, axilla, or groin
* [[Swollen lymph nodes]] in the neck, axilla, or groin
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Ascites]]
* [[Ascites]]
* [[Proptosis]]
* [[Proptosis]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 323: Line 302:
* [[basophilic]] cytoplasm
* [[basophilic]] cytoplasm
* "Starry-sky pattern"
* "Starry-sky pattern"
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 332: Line 310:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 364: Line 339:
|
|
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 398: Line 370:
** Deletion 7q21-32
** Deletion 7q21-32
** Translocations of the CDK6 gene located on 7q21  
** Translocations of the CDK6 gene located on 7q21  
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 426: Line 396:
* Epithelial histocytes
* Epithelial histocytes
* Plasmacytic differentiation of neoplastic cells
* Plasmacytic differentiation of neoplastic cells
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 441: Line 410:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 448: Line 418:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Hemorrhage
* Hemorrhage
* Dyspepsia
* Dyspepsia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 463: Line 430:
* Follicular cells in reactive zone
* Follicular cells in reactive zone
* Centrocyte like cells in marginal zone lymphoma
* Centrocyte like cells in marginal zone lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 476: Line 442:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 531: Line 494:
* [[Petechiae]]
* [[Petechiae]]
* [[Splenomegaly]]
* [[Splenomegaly]]
|
|
|
|
|
Line 541: Line 503:
** Decreased [[platelets]] count
** Decreased [[platelets]] count
**  
**  
|
|
|
|
|
Line 560: Line 521:
:* Central round [[nucleus]]
:* Central round [[nucleus]]
:* Peri-nuclear clearing ("water-clear rim" appearance)
:* Peri-nuclear clearing ("water-clear rim" appearance)
|
|
|
|
|
Line 568: Line 528:
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
|
|
* '''Precursor T-cell Lymphomas'''
* Precursor T-cell Lymphomas


|
|
|
|
|
|
|
Line 599: Line 556:
|
|
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
|
|
|
|
|
|
|
Line 629: Line 583:
|T cell lymphoma
|T cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
|
|
|
|
|
|
|
Line 684: Line 635:
|
|
* Cutaneous manifestations
* Cutaneous manifestations
|
|
|
|
|
|
|
Line 704: Line 652:
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 734: Line 679:
|
|
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 764: Line 706:
|
|
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 794: Line 733:
|
|
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 824: Line 760:
|
|
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 854: Line 787:
|
|
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |

Revision as of 18:36, 7 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Category Disease Etiology Mechanism Clinical manifestations Paraclinical findings Gold standard Associated findings
Lab findings
Demography History Symptoms Signs CBC PBS PT/PTT Immunochemistry Histopathology Other
Inherited Acquired Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass LAP Hepatosplenomegaly Other WBC Hb Plt
HL
Hodgkin's Lymphoma
NHL
B Cell Lymphoma Precursor B-cell lymphoblastic leukemia/lymphoma
  • Precursor B-cell Lymphoma
Follicular lymphoma
  • Mature B-cell Lymphoma
  • Reciprocal translocation t(14;18)(q32;q21)
  • Second most common subtype of NHL
+ +
  • Painless swelling in the neck, axilla, groin, thorax and abdomen
  • Central and peripheral lymphadenopathy
+
  • Most common clinically indolent NHL
Mantle cell lymphoma
  • Fatigue
  • Night sweats
  • Weight Loss
Abdominal distention
  • Palpable masses in skin, breast, and salivary glands
Generalized lymphadenopathy +
  • Extranodal involvement of GI tract, lungs, and CNS
  • Mental Retardation
  • Lymphocytosis > 4000/µL
Nl to ↓
  • CD5+
  • B-cell antigen positive
  • Overexpression of Cyclin D1
  • Germinal centers filled by small-to-medium atypical lymphocytes
  • Nodular appearance
Elevated LDH
Diffuse large B cell lymphoma
  • Mature B-cell Lymphoma
  • 8q24/MYC translocations
  • Hypermutated immunoglobulin genes
  • Mutation of BCL6, MYC, PAX5, PIM1, RhoH /TTFn, TP53 genes
  • Translocations involving c-MYC, BCL6, and IgH gene.
  • Fever
  • Night sweats
  • weight loss
Nl to ↓

Centroblastic

Immunoblastic

  • > 90% immunoblasts
  • Trapezoid shaped large lymphoid cells with significant basophilic cytoplasm

Anaplastic

  • Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells
  • Hypergammaglobulinemia
Category Disease Etiology Inherited Acquired Demography History Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass LAP Hepatosplenomegaly Other WBC Hb Plt PBS PT/PTT Immunochemistry Histopathology Other lab findings Gold standard Associated findings
Burkitt lymphoma
  • Mature B-cell Lymphoma
  • Translocation of chromosome 8 myc locus such as:
    • t(8;14)
    • t(2;8)
    • t(8;22)
  • Round and small nucleoli
  • basophilic cytoplasm
  • "Starry-sky pattern"
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mature B-cell Lymphoma
Marginal zone lymphoma Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
  • Mature B-cell Lymphoma
Splenic marginal zone lymphoma
  • Mature B-cell Lymphoma
  • Clonal rearrangements of the immunoglobulin genes (heavy and light chains)
    • Deletion 7q21-32
    • Translocations of the CDK6 gene located on 7q21
  • Small lymphocytes
  • Transformed blasts
  • Epithelial histocytes
  • Plasmacytic differentiation of neoplastic cells
Nodal marginal zone B-cell lymphoma
  • Mature B-cell Lymphoma
  • Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40
+
  • Hemorrhage
  • Dyspepsia
  • AE1/AE3
  • Expression of B-cell markers CD20, CD79a, CD10, CD23, and bcl-2
  • Follicular cells in reactive zone
  • Centrocyte like cells in marginal zone lymphoma
  • Chronic infectious conditions or autoimmune processes, such as
    • H pylori gastritis
  • Hashimoto thyroiditis
  • Sjögren syndrome
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
  • Mature B-cell Lymphoma
Hairy cell leukemia
  • Production of cytokines, such as TNF alpha and IL-2R, provide important stimuli for malignant B cells proliferation in hairy cell leukemia.
    • The p38-MAPK-JNK cascade
    • The MEK-ERK cascade
    • The Phosphatidylinositol 3 kinase (PI3K)-AKT cascade
  • Tartrate-resistant acid phosphatase positive
  • CBC
  • Small cells with "fried egg"-like appearance
  • Well-demarcated thread-like cytoplasmic extensions
  • Clear cytoplasm
  • Central round nucleus
  • Peri-nuclear clearing ("water-clear rim" appearance)
Precursor T-cell lymphoblastic leukemia/lymphoma
  • Precursor T-cell Lymphomas
Adult T cell leukemia/lymphoma
T cell lymphoma Anaplastic large cell lymphoma
Cutaneous T-cell lymphoma Mycosis fungoides / Sézary syndrome
  • Cutaneous manifestations
Peripheral T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma
Hepatosplenic gamma-delta T-cell lymphoma
Enteropathy-type intestinal T-cell lymphoma
Extranodal T-cell lymphoma, nasal type
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma, unspecified